Cho, R.; Sakurai, Y.; Jones, H.S.; Akita, H.; Hisaka, A.; Hatakeyama, H.
Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. Cancers 2020, 12, 3630.
https://doi.org/10.3390/cancers12123630
AMA Style
Cho R, Sakurai Y, Jones HS, Akita H, Hisaka A, Hatakeyama H.
Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. Cancers. 2020; 12(12):3630.
https://doi.org/10.3390/cancers12123630
Chicago/Turabian Style
Cho, Riki, Yu Sakurai, Haleigh Sakura Jones, Hidetaka Akita, Akihiro Hisaka, and Hiroto Hatakeyama.
2020. "Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors" Cancers 12, no. 12: 3630.
https://doi.org/10.3390/cancers12123630
APA Style
Cho, R., Sakurai, Y., Jones, H. S., Akita, H., Hisaka, A., & Hatakeyama, H.
(2020). Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. Cancers, 12(12), 3630.
https://doi.org/10.3390/cancers12123630